Share This Page

Connecting Alzheimer's & Dementia Organizations to Supporters & Clients

What Blocks Alzheimer’s in Organ Transplants?

First heart transplant, 1967, South Africa

A startling new link shows Alzheimer’s in transplant patients is significantly lower, in fact almost absent, when compared to national data from the general population. Learn more.


A new study from The University of Texas Medical Branch at Galveston has revealed that a treatment taken daily by people who have had organ transplants to prevent organ rejection protects against Alzheimer’s disease. An early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer’s Disease.

Alzheimer’s disease is the most common age-associated neurodegenerative disorder that has no cure. Compelling evidence shows that toxic protein aggregates called Aβ oligomers selectively target and disrupt the points of communication between brain cells, impairing memory in people suffering from the disease. Because of this, there is a large consensus that preventing this kind of toxicity would be an effective treatment strategy.

Calcineurin

Calcineurin is an enzyme that regulates communication between brain cells and memory formation. The UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the Aβ oligomers and that elevated calcineurin is found in the nervous system of Alzheimer’s patients.

Using a mouse model of Alzheimer’s, the researchers earlier showed that blocking calcineurin restored memory function. However, the question of whether such a strategy would prevent the onset and progression of Alzheimer’s in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.

2,644 Organ Transplant Patients

To bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ. As part of the medical care for transplant recipients, any evidence of memory impairment or dementia is immediately noted and monitored, as it can limit treatment compliance among these patients.

The participants were separated into groups by age at the time of last visit or death, gender and ethnicity. Eight participants showed evidence of dementia – two were younger than 65, five were in the 65-74 years old group and one was in the 75-84 years old group.

The UTMB study data was compared with national data obtained from the 2014 Alzheimer’s Association Facts and Figures dataset on age-matched patients to compare the prevalence of Alzheimer’s.

“These data clearly show that the prevalence of dementia and Alzheimer’s in our transplant patient group is significantly lower, in fact almost absent, when compared to national data from the general population,” said senior author Luca Cicalese, professor in the department of surgery. “In patients over 65 years, 11 percent of the general population had dementia compared with 1.02 percent of the study subjects. In Americans over 75 years, 15.3 percent of the population had dementia compared with 0.6 percent of the study subjects. Among Americans over 85 years, 32 percent had dementia, although we did not have any patients in this age group with dementia.”

Since the people involved in the study mostly come from Texas, the researchers further compared their over 65 years old group with the prevalence of Alzheimer’s in the general population of the state and got similar results.

Confirmation

“Taken together, our findings from these people confirm the data obtained with animal models and support, for the first time in human subjects, our notion that calcineurin inhibition has a protective effect on the development and possible progression and even reversal of Alzheimer’s disease,” said senior author Giulio Taglialatela, Professor and Vice Chair for Research in the department of neurology and director of UTMB’s Mitchell Center for Neurodegenerative Diseases. “Therefore, we are currently working on devising treatment strategies to obtain the same beneficial effects in AD humans using low doses of calcineurin inhibitors that result in minimal or no immunosuppression, thus limiting possible undesired side effects.”

MORE INFORMATION:
UTMB’s Cristiana Rastellini, Professor in the departments of Surgery and Microbiology & Immunology also was an author on this paper.

This research was supported by the National Institutes of Health and the Mitchell Center for Neurodegenerative Diseases.

SOURCE:
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

Related:

Email me when people comment
Notify of
guest

3 Comments
Inline Feedbacks
View all comments
Unknown
Unknown
March 31, 2018 2:23 am

Norepinephrine is produced in the adrenal glands, hence is other name, adrenaline.

Anonymous
Anonymous
May 17, 2016 10:59 pm

Respectfully, I suggest an alternative explanation: That it is the corrected organ which prevents the onset of dementia. More than 80% of the organs being transplanted are kidneys. What do kidneys have to do with dementia? Everything: norepinephrine is produced in the kidneys – both a key (we are learning from new research into memories) neurotransmitter AND (this is important) a key anti-inflammatory chemical in the brain. It is well understood that one of the very first indications of Alzheimer's is a decrease in norepinephrine production in the brain; that 70% of people with Type II diabetes will get Alzheimer's (kidney damage). Perhaps it isn't a drug, but an organ's own function that is avoiding a disease.

Eric
Eric
Reply to  Anonymous
November 6, 2023 8:37 am

So is reduced kidney function associated with low norepinephrine? Yeah the adrenal glands are on top of the kidneys but I think the operation of both are fairly independent (I’m not a doctor though). But speaking of noradrenaline, I think another study showed that atomoxetine, which is a noradrenaline reuptake inhibitor, also has Alzheimer’s-reducing effects.

Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

You May LIke:

Therapeutic Dementia Garden
Uncategorized

How to Build a Professional Dementia Garden

The Therapeutic Gardens project in Italy has been studied, certified and recognized for excellence. Dementia patients improve memory, cognitive functions, language, mood and above all, they need less medication.

Read More »
Professionals

Alzheimer’s Patient #1

In 1906, Dr. Alois Alzheimer first identified Alzheimer’s disease. A 51-year-old woman, Auguste Deter, exhibited behavioral symptoms and memory loss.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

3
0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter